SCHEMBL6140897

SCHEMBL6140897

Cc1cc(Nc2ccccc2C(=O)O)c(Nc2ccccc2C(=O)O)cc1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 5/20 0.70
AKR1C2 P52895 4/20 0.70
MEN1 O00255 3/20 0.70
AKR1B10 O60218 3/20 0.70
PTGS2 P35354 3/20 0.70
KMT2A Q03164 3/20 0.70
AKR1C1 Q04828 3/20 0.70
LMNA P02545 2/20 0.70
CYP1A2 P05177 2/20 0.70
CYP3A4 P08684 2/20 0.70
CYP2C9 P11712 2/20 0.70
AKR1B1 P15121 2/20 0.70
HIF1A Q16665 2/20 0.70
ABCB11 O95342 2/20 0.70
CHRM1 P11229 2/20 0.70
PTGS1 P23219 2/20 0.70
TRPA1 O75762 1/20 0.70
DHFR P00374 1/20 0.70
MPO P05164 1/20 0.70
NAPRT Q6XQN6 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11105154 0.93 AKR1C3 (0.66) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL29834970 0.87 AKR1C3 (0.77) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL1186480 0.87 AKR1C3 (0.77) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL30320327 0.86 FABP4 (0.80) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL355549 0.86 FABP4 (0.80) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL6141201 0.84 FABP4 (0.62) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL6142375 0.84 FABP4 (0.84) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL9691899 0.84 FABP4 (0.77) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL11794308 0.84 AKR1C3 (0.63) AKR1C3AKR1C2MEN1AKR1B10PTGS2
SCHEMBL14580629 0.83 TAS2R14 (0.70) AKR1C3AKR1C2MEN1AKR1B10PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP claimed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO claimed
EP-1525183-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-04-27 EP disclosed
US-20040142993-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002940-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142993-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 AKR1C3 2623/4885AKR1C2 2961/4885MEN1 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.